MDM2 regulates a novel form of incomplete neoplastic transformation of Theileria parva infected lymphocytes

Experimental and Molecular Pathology

Volumn 94, Issue 1, 2013, Pages 228-238

  Hayashida, Kyoko ^a   Kajino, Kiichi ^a   Hattori, Masakazu ^b   Wallace, Maura ^c   Morrison, Ivan ^d   Greene, Mark I ^e   Sugimoto, Chihiro ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Lymhoproliferation; MDM2; P53; Theileria parva

Indexed keywords

ANTIPROTOZOAL AGENT; BUPARVAQUONE; CHALCONE; CISPLATIN; ISOPROTEIN; PROTEIN BAX; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPLASM; EAST COAST FEVER; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE PROLIFERATION; LYMPHOMA CELL; MALIGNANT TRANSFORMATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THEILERIA PARVA; TUMOR CELL; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CATTLE; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CISPLATIN; DNA DAMAGE; ENZYME ACTIVATION; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; NAPHTHOQUINONES; NF-KAPPA B; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; THEILERIA PARVA; TUMOR SUPPRESSOR PROTEIN P53;

BOS; IXODIDA; PROTOZOA; THEILERIA PARVA;

EID: 84870983944     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.08.008     Document Type: Article

References (58)

1. Bartel F., et al. Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines. Oncology Research 2001, 12:451-457.
2. Bartel F., et al. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2002, 2:9-15.
3. Bode A.M., Dong Z. Post-translational modification of p53 in tumorigenesis. Nature Reviews Cancer 2004, 4:793-805.
4. Bouska A., et al. Mdm2 promotes genetic instability and transformation independent of p53. Molecular and Cellular Biology 2008, 28:4862-4874.
5. Brown W.C., Logan K.S. Bovine T-cell clones infected with Theileria parva produce a factor with IL 2-like activity. Parasite Immunology 1986, 8:189-192.
6. Brown C.G., et al. Letter: Infection and transformation of bovine lymphoid cells in vitro by infective particles of Theileria parva. Nature 1973, 245:101-103.
7. Busuttil V., et al. NF-κB inhibits T-cell activation-induced, p73-dependent cell death by induction of MDM2. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:18061-18066.
8. Cahilly-Snyder L., et al. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somatic Cell and Molecular Genetics 1987, 13:235-244.
9. Chang C.J., et al. PTEN regulates Mdm2 expression through the P1 promoter. Journal of Biological Chemistry 2004, 279:29841-29848.
10. del Aguila C., et al. Encephalitozoon microsporidia modulates p53-mediated apoptosis in infected cells. International Journal of Parasitology 2006, 36:869-876.
11. Dobbelaere D., Heussler V. Transformation of leukocytes by Theileria parva and T. annulata. Annual Review of Microbiology 1999, 53:1-42.
12. Dobbelaere D.A., Kuenzi P. The strategies of the Theileria parasite: a new twist in host-pathogen interactions. Current Opinion in Immunology 2004, 16:524-530.
13. Dobbelaere D.A., et al. Theileria parva: taking control of host cell proliferation and survival mechanisms. Cellular Microbiology 2000, 2:91-99.
14. Fakharzadeh S.S., et al. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO Journal 1991, 10:1565-1569.
15. Feng J., et al. Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation. Journal of Biological Chemistry 2004, 279:35510-35517.
16. Forte E., Luftig M.A. MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B cell growth transformation and infected cell survival. Journal of Virology 2009, 83:2491-2499.
17. Ganguli G., Wasylyk B. p53-independent functions of MDM2. Molecular Cancer Research 2003, 1:1027-1035.
18. Gottlieb T.M., Oren M. p53 in growth control and neoplasia. Biochimica et Biophysica Acta 1996, 1287:77-102.
19. Gu L., et al. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia 2008, 22:730-739.
20. Guergnon J., et al. Apoptosis of Theileria-infected lymphocytes induced upon parasite death involves activation of caspases 9 and 3. Biochimie 2003, 85:771-776.
21. Haller D., et al. Cytoplasmic sequestration of p53 promotes survival in leukocytes transformed by Theileria. Oncogene 2010, 29:3079-3086.
22. Haupt Y., et al. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
23. Heussler V.T., et al. The intracellular parasite Theileria parva protects infected T cells from apoptosis. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:7312-7317.
24. Heussler V.T., et al. The Akt/PKB pathway is constitutively activated in Theileria-transformed leucocytes, but does not directly control constitutive NF-kappaB activation. Cellular Microbiology 2001, 3:537-550.
25. Heussler V.T., et al. Inhibition of apoptosis by intracellular protozoan parasites. International Journal of Parasitology 2001, 31:1166-1176.
26. Heussler V.T., et al. Hijacking of host cell IKK signalosomes by the transforming parasite Theileria. Science 2002, 298:1033-1036.
27. Honda R., Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 2000, 19:1473-1476.
28. Hulliger L., et al. Mode of multiplication of Theileria in cultures of bovine lymphocytic cells. Nature 1964, 203:728-730.
29. Irvin A.D., et al. Comparative growth of bovine lymphosarcoma cells and lymphoid cells infected with Theileria parva in athymic (nude) mice. Nature 1975, 255:713-714.
30. Ivanov V., et al. Infection with the intracellular protozoan parasite Theileria parva induces constitutively high levels of NF-kappa B in bovine T lymphocytes. Molecular and Cellular Biology 1989, 9:4677-4686.
31. Jones S.N., et al. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:15608-15612.
32. Juven T., et al. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 1993, 8:3411-3416.
33. Katzer F., et al. Extensive genotypic diversity in a recombining population of the apicomplexan parasite Theileria parva. Infection and Immunity 2006, 74:5456-5464.
34. Komori H., et al. Predominant p53 mutations in enzootic bovine leukemic cell lines. Veterinary Immunology and Immunopathology 1996, 52:53-63.
35. Kumar S.K., et al. Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. Journal of Medicinal Chemistry 2003, 46:2813-2815.
36. Lawrence J.A., Irvin A.D. Theilerioses. Infectious Diseases of Livestock 1994, 307-341. Oxford university press, New York. J.A.W. Coetzer (Ed.).
37. Mayo L.D., Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:11598-11603.
38. Momand J., et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
39. Ogawara Y., et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. Journal of Biological Chemistry 2002, 277:21843-21850.
40. Phelps M., et al. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Research 2003, 63:2616-2623.
41. Rocchi M.S., et al. The kinetics of Theileria parva infection and lymphocyte transformation in vitro. International Journal of Parasitology 2006, 36:771-778.
42. Sasayama T., et al. Trans-4-lodo,4'-boranyl-chalcone induces antitumor activity against malignant glioma cell lines in vitro and in vivo. Journal of Neuro-Oncology 2007, 85:123-132.
43. Shiels B., et al. Alteration of host cell phenotype by Theileria annulata and Theileria parva: mining for manipulators in the parasite genomes. International Journal of Parasitology 2006, 36:9-21.
44. Shimizu H., et al. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. Journal of Biological Chemistry 2002, 277:28446-28458.
45. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
46. Sigalas I., et al. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nature Medicine 1996, 2:912-917.
47. Steinman H.A., et al. An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. Journal of Biological Chemistry 2004, 279:4877-4886.
48. Tao W., Levine A.J. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:3077-3080.
49. Teodoro J.G., Branton P.E. Regulation of apoptosis by viral gene products. Journal of Virology 1997, 71:1739-1746.
50. Tergaonkar V., et al. p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 2002, 1:493-503.
51. Toledo F., Wahl G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nature Reviews Cancer 2006, 6:909-923.
52. Veldhoen N., et al. A novel exon within the mdm2 gene modulates translation initiation in vitro and disrupts the p53-binding domain of mdm2 protein. Oncogene 1999, 18:7026-7033.
53. Vogelstein B., et al. Surfing the p53 network. Nature 2000, 408:307-310.
54. von Schubert C., et al. The transforming parasite Theileria co-opts host cell mitotic and central spindles to persist in continuously dividing cells. PLoS Biology 2010, 8:e1000499.
55. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nature Reviews Cancer 2002, 2:594-604.
56. Weber J.D., et al. Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biology 1999, 1:20-26.
57. Wu X., et al. The p53-mdm-2 autoregulatory feedback loop. Genes & Development 1993, 7:1126-1132.
58. Yaswen P., Campisi J. Oncogene-induced senescence pathways weave an intricate tapestry. Cell 2007, 128:233-234.